FLT3 and acute myeloid leukemia: Gilteritinib is a potent and selective FLT3 inhibitor with activity against both FLT3-ITD and FLT3-TKD mutations that demonstrated clinical efficacy in subjects with both wild-type or mutated FLT3 in phase 1/2 clinical trials enrolling adult patients with relapsed or refractory AML (25).